---
document_datetime: 2024-11-25 17:34:27
document_pages: 26
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/xigduo-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: xigduo-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 14.536467
conversion_datetime: 2025-12-19 10:35:18.424491
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Xigduo

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| WS/2664              | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of sections 4.2, 4.4, 4.5, 4.8, 5.1 and 6.1 of the SmPC in order to align dapagliflozin related | 18/07/2024                          |                                             | SmPC and PL                      |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|         | information in Fixed Dose Combination with Forxiga. The Package Leaflet is updated accordingly. The RMPs version 15.1 (Xigduo and Wbymect) and 9.1 (Qtern) have also been submitted. In addition, the MAH took the opportunity to introduce editorial changes to the PI. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                        |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/2544 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of sections 4.4 and 4.8 of the SmPC in order to add a new warning on 'Vitamin B12 decrease/deficiency' and to change the frequency of 'Vitamin B12 decrease/deficiency' in the list of adverse drug reactions (ADRs) from frequency 'very rare' to 'common'. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI and to update the contact details of the local representative in the Netherlands in the Package Leaflet. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 08/02/2024 | 29/08/2024 | SmPC and PL | Metformin may reduce vitamin B12 serum levels. The risk of low vitamin B12 levels increases with increasing metformin dose, treatment duration, and/or in patients with risk factors known to cause vitamin B12 deficiency. In case of suspicion of vitamin B12 deficiency (such as anaemia or neuropathy), vitamin B12 serum levels should be monitored. Periodic vitamin B12 monitoring could be necessary in patients with risk factors for vitamin B12 deficiency. Metformin therapy should be continued for as long as it is tolerated and not contraindicated and appropriate corrective treatment for vitamin B12 deficiency provided in line with current clinical guidelines. |

<div style=\"page-break-after: always\"></div>

| IG/1693   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                     | 06/02/2024   | 29/08/2024   | SmPC and PL     |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-----------------|
| IG/1630   | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                                                   | 26/06/2023   | n/a          |                 |
| IG/1616   | A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release                                                                                                                                                                                                         | 30/05/2023   | 29/08/2024   | Annex II and PL |
| WS/2382   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                       | 12/01/2023   | 03/02/2023   | SmPC and PL     |
| IG/1558   | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                                                                                                               | 06/10/2022   | n/a          |                 |
| WS/2279/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place | 07/07/2022   | n/a          |                 |

<div style=\"page-break-after: always\"></div>

|           | B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary packaging, for non-sterile medicinal products                                                                                                                                                                                                             |            |            |                 |           |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-----------|
| WS/2234/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. A.7 - Administrative change - Deletion of manufacturing sites B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other | 02/06/2022 | n/a        |                 | variation |
| WS/2230   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation                                                                                                                                                                              | 22/04/2022 | n/a        |                 |           |
| IG/1479/G | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                      | 26/01/2022 | 03/02/2023 | Annex II and PL |           |

<div style=\"page-break-after: always\"></div>

|                     | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                         |            |            |                 |                                   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-----------------------------------|
| PSUSA/10294 /202101 | Periodic Safety Update EU Single assessment - dapagliflozin / metformin                                                                                                                                                                                                                                                                                                                                                                               | 02/09/2021 | n/a        |                 | PRAC Recommendation - maintenance |
| IG/1410/G           | This was an application for a group of variations. B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging | 17/06/2021 | n/a        |                 |                                   |
| IG/1367             | B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size                                                                                                                                                                                                                                                                                          | 15/03/2021 | n/a        |                 |                                   |
| IG/1343             | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                                                                                | 05/02/2021 | 03/02/2022 | Annex II and PL |                                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| WS/1853/G This was an application following a worksharing Article 20 of Commission 1234/2008. B.I.a.1.z - Change in starting material/reagent/intermediate variation B.I.b.2.a - Change in starting material/reagent/intermediate changes to an approved B.I.b.2.a - Change in starting material/reagent/intermediate changes to an approved B.I.b.2.c - Change in starting material/reagent/intermediate changes to a test procedure does not have a significant quality of the AS B.I.b.2.c - Change in starting material/reagent/intermediate changes to a test procedure does not have a significant quality of the AS B.I.b.2.c - Change in starting material/reagent/intermediate changes to a test procedure does not have a significant quality of the AS B.I.b.2.c - Change in starting material/reagent/intermediate   | 03/09/2020   | n/a   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|

<div style=\"page-break-after: always\"></div>

|                     | does not have a significant effect on the overall quality of the AS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |            |            |                 |                                   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-----------------------------------|
| PSUSA/10294 /202001 | Periodic Safety Update EU Single assessment - dapagliflozin / metformin                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 03/09/2020 | n/a        |                 | PRAC Recommendation - maintenance |
| WS/1843/G           | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary packaging, for non-sterile medicinal products B.III.1.a.3 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from a | 23/07/2020 | n/a        |                 |                                   |
| WS/1742             | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                            | 14/05/2020 | n/a        |                 |                                   |
| IG/1200/G           | This was an application for a group of variations. A.7 - Administrative change - Deletion of                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 07/02/2020 | 30/09/2020 | Annex II and PL |                                   |

<div style=\"page-break-after: always\"></div>

|           | sites B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                                                                                                                                                                                                        |            |            |             | manufacturing   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------|
| IG/1199   | B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 07/02/2020 | n/a        |             |                 |
| WS/1715/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.d.1.d - Change in the specification parameters and/or limits of the finished product - Deletion of a non-significant specification parameter B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate an already approved manufacturer | 16/01/2020 | n/a        |             | from            |
| IG/1171   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 11/12/2019 | 30/09/2020 | SmPC and PL |                 |

<div style=\"page-break-after: always\"></div>

| WS/1697             | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary packaging, for non-sterile medicinal products                                                                                                                                                                                                                                                                                                               | 17/10/2019   | n/a        |             |                                                                                                                                                                                                                                                                                                               |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/1637             | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of sections 4.4 (Special warnings and precautions for use) and 4.8 (Undesirable effects) of the SmPC of dapagliflozin-containing products with respect to the Fournier's gangrene class labelling language, following results from the DECLARE study (a Multicentre, Randomized, Double-Blind, Placebo- Controlled cardiovascular outcome trial in Patients with Type 2 Diabetes). The Package Leaflet is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 17/10/2019   | 30/09/2020 | SmPC and PL | Information on Fournier`s gangrene in section 4.8 was updated with the frequency 'very rare', based on the DECLARE study and information was added under 'Description of selected adverse reactions' ; a reference to section 4.8 was added in SmPC section 4.4. The Package Leaflet was updated accordingly. |
| PSUSA/10294 /201901 | Periodic Safety Update EU Single assessment - dapagliflozin / metformin                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 05/09/2019   | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| WS/1539   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of sections 4.1 , 4.2, 4.4, 4.8, and 5.1 of the SmPC of Forxiga, Edistride, Xigduo and Ebymect to modify the indication and to reflect new data based   | 27/06/2019   | 25/07/2019   | SmPC and PL   | Please refer to the Scientific Disdcussion 'EMEA/H/C/xxxx/WS/1539'   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|---------------|----------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| IG/1067   | B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 19/03/2019   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/1064   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 01/03/2019   | 25/07/2019 | SmPC and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| WS/1380   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of sections 4.2, 4.4 and 5.1 of the SmPC in order to reflect the final study results from study D1690C00024 (DERIVE); A Multicentre, Double- Blind, Placebo-Controlled, Parallel Group, Randomized, Phase III Study to Evaluate the Glycaemic Efficacy and Renal Safety of Dapagliflozin in Patients with Type 2 Diabetes Mellitus and Moderate Renal Impairment (CKD 3A) Who Have Inadequate Glycaemic Control. In addition, the Worksharing applicant took the opportunity to implement minor editorial changes in Edistride, Ebymect and Xigduo PI and to update the list of local representatives in the Package Leaflets for Edistride and Ebymect. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 20/09/2018   | 12/11/2018 | SmPC and PL | Based on the results from study D1690C00024 (DERIVE) the following dosage recommendation in case of renal impairment has been updated in section 4.2 and 4.4. Forxiga, Edistride: dapagliflozin should not be initiated in patients with a glomerular filtration rate [GFR] < 60 mL/min and should be discontinued at GFR persistently below 45 mL/min. No dosage adjustment is required based on renal function. Xigduo, Ebymect: the maximum daily dose of metformin should preferably be divided into 2-3 daily doses. Factors that may increase the risk of lactic acidosis should be reviewed before considering initiation of metformin in patients with GFR < 60 mL/min. The results of study D1690C00024 (DERIVE) have been reflected in section 5.1 of Edistride, Ebymect, Forxiga and Xigduo |

<div style=\"page-break-after: always\"></div>

| R/0044              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                        | 26/07/2018   | 28/09/2018   | SmPC, Labelling and PL   | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Xigduo in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity.   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10294 /201801 | Periodic Safety Update EU Single assessment - dapagliflozin / metformin                                                                                                                                                                                                                                                                        | 06/09/2018   | n/a          |                          | PRAC Recommendation - maintenance                                                                                                                                                                                                                                      |
| WS/1345/G           | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.d.z - Stability of AS - Other variation B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol | 19/04/2018   | n/a          |                          |                                                                                                                                                                                                                                                                        |
| IG/0892             | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                   | 28/02/2018   | n/a          |                          |                                                                                                                                                                                                                                                                        |
| PSUSA/10294 /201707 | Periodic Safety Update EU Single assessment - dapagliflozin / metformin                                                                                                                                                                                                                                                                        | 08/02/2018   | n/a          |                          | PRAC Recommendation - maintenance                                                                                                                                                                                                                                      |
| IG/0894             | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or                                                                                                                                     | 05/02/2018   | n/a          |                          |                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

|           | manufacturer of a novel excipient                                                                                                                                                                                                                                                                        |            |            |                        |                                              |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|----------------------------------------------|
| WS/1271/G | for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation C.I.z - Changes (Safety/Efficacy) of Human and Products - Other variation | 23/11/2017 | 20/12/2017 | SmPC, Labelling and PL | This was an application Veterinary Medicinal |
| WS/1229   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority              | 30/11/2017 | n/a        |                        |                                              |
| WS/1259   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission competent authority                                | 30/11/2017 | n/a        |                        | of studies to the                            |
| IG/0841   | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                         | 24/10/2017 | n/a        |                        |                                              |

<div style=\"page-break-after: always\"></div>

| WS/1167   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of sections 4.8 and 5.1 of the SmPC in order to add information regarding two initial combination studies (MB102021 and MB102034) in treatment- na√Øve patients of dapagliflozin 5 mg + metformin and dapagliflozin 10 mg + metformin, respectively, compared to each component separately. In addition, the Worksharing applicant (WSA) took the opportunity to bring the PI in line with the latest QRD template version 10. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance   | 12/10/2017   | 20/12/2017   | SmPC and Labelling   | data       |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|----------------------|------------|
| WS/1196/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation B.II.d.2.b - Change in test procedure for the finished product - Deletion of a test procedure if an alternative method is already authorised B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure replacement or addition)                                                                                                                                                      | 14/09/2017   | n/a          |                      | (including |

<div style=\"page-break-after: always\"></div>

| PSUSA/10294 /201701   | Periodic Safety Update EU Single assessment - dapagliflozin / metformin                                                                                                                                                                                                                     | 01/09/2017   | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|-----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/1198               | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation | 20/07/2017   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| WS/1092               | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                             | 20/07/2017   | 20/12/2017 | SmPC and PL | In study D5553C00003, the combination of dapagliflozin and prolonged release exenatide (a GLP 1 receptor agonist) was compared to dapagliflozin alone and prolonged release exenatide alone in subjects with inadequate glycaemic control on metformin alone (Hb A1c ‚â• 8% and ‚â§ 12%). All treatment groups had a reduction in HbA1c compared to baseline. The combination treatment with dapagliflozin 10 mg and prolonged release exenatide group showed superior reductions in HbA1c from baseline compared to dapagliflozin alone and prolonged release exenatide alone. Combination therapy of dapagliflozin 10 mg and prolonged release exenatide resulted in significantly greater reductions in fasting plasma glucose, in 2 hour post prandial glucose, in body weight and systolic blood pressure at week 28, as compared to either agent alone. These efficacy results were reflected in section 5.1 of the SmPC. In addition the statement that combination with glucagon like peptide 1 (GLP 1) analogues had not been studied, was removed from section 4.4 as result of the availability of this study. |

<div style=\"page-break-after: always\"></div>

| WS/1055   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 21/04/2017   | 20/12/2017   | SmPC, Labelling and PL   |                                                                            |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------------------------|----------------------------------------------------------------------------|
| A20/0024  | Pursuant to Article 20 of Regulation (EC) No 726/2004, the European Commission requested on 15 April 2016 the PRAC to assess the impact on the benefit-risk balance of canagliflozin containing medicinal products of an increase in amputations, mostly affecting the toes, observed in an ongoing clinical trial (CANVAS) for canagliflozin and a numerical imbalance with regards to amputation events seen in an ongoing renal study CANVAS-R with a similar population as CANVAS. Considering that a class effect cannot be excluded, the European Commission extended on 6 July 2016 the scope of the procedure to include all SGLT2 inhibitors containing medicinal products to allow a review of data from the class. The PRAC was requested to assess the impact thereof on the benefit-risk balance of Invokana, Vokanamet, Forxiga, Edistride, Xigduo, Ebymect, Jardiance and Synjardy and to give its recommendation whether the marketing authorisation of these products should be maintained, varied, suspended or revoked. As the request results from the evaluation of data | 09/02/2017   | 20/04/2017   | SmPC and PL              | Please refer to the assessment report: SGLT2 inhibitors - EMEA/H/A-20/1442 |

<div style=\"page-break-after: always\"></div>

|                     | CHMP opinion has been be adopted on the basis of a recommendation of the Pharmacovigilance Risk Assessment Committee.                                                                                                                                                                       |            |            |                        |                                                                                                                                                                                                                                                                                                                                                                 |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0921             | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation                          | 06/04/2017 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                 |
| WS/1103             | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation | 23/03/2017 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                 |
| PSUSA/10294 /201607 | Periodic Safety Update EU Single assessment - dapagliflozin / metformin                                                                                                                                                                                                                     | 09/02/2017 | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                               |
| WS/1056             | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                             | 19/01/2017 | 20/04/2017 | SmPC, Labelling and PL | Based on literature data, information on interaction on the interaction between 1,5-anhydroglucitol assay (monitoring glycaemic control method) and the SGLT2 inhibitors was added in section 4.5 of the Summary Product Characteristics as follows: Interference with 1,5-anhydroglucitol (1,5-AG) assay Monitoring glycaemic control with 1,5-AG assay is not |

<div style=\"page-break-after: always\"></div>

|             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |            |            |             | recommended as measurements of 1,5-AG are unreliable in assessing glycaemic control in patients taking SGLT2 inhibitors. Use alternative methods to monitor glycaemic control.   |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| A31/0018    | Pursuant to Article 31 of Regulation (EC) No 726/2004, the European Commission requested on 25 January 2016 the opinion of the European Medicines Agency on the adequacy of the current recommendations for metformin containing products with respect to the use in patients with moderate renal failure, taking into account the available information on the risk of lactic acidosis. The CHMP was requested to assess the impact thereof on the benefit-risk balance of metformin containing products and to give its recommendation whether the marketing authorisation of this product should be maintained, varied, suspended or revoked. The notification for the procedure is appended to this opinion. | 13/10/2016 | 12/12/2016 | SmPC and PL | Please refer to the assessment report: Metformin containing medicinal products - EMEA/H/A- 31/1432                                                                               |
| WS/0968     | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                      | 10/11/2016 | n/a        |             |                                                                                                                                                                                  |
| PSUSA/10294 | Periodic Safety Update EU Single assessment -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 02/09/2016 | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

| /201601   | dapagliflozin / metformin                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |            |            |             |                                                                            |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------------|
| WS/0931/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary packaging, for non-sterile medicinal products B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.3.z - Change in the manufacturing process of                                                         | 21/07/2016 | n/a        |             |                                                                            |
| A20/0012  | Pursuant to Article 20 of Regulation (EC) No 726/2004, the European Commission requested on 10 June 2015 the opinion of the European Medicines Agency on the risk of Diabetic ketoacidosis (DKA) in patients treated with sodium-glucose co-transporter 2 (SGLT2) inhibitors and requested the Agency to assess the impact thereof on the benefit-risk balance of canagliflozin-containing medicinal products (Invokana and Vokanamet), dapagliflozin-containing medicinal products (Forxiga and Xigduo), and empagliflozin-containing medicinal products (Jardiance and Synjardy) and to issue a recommendation on whether the relevant marketing | 25/02/2016 | 28/04/2016 | SmPC and PL | Please refer to the assessment report: SGLT2 inhibitors - EMEA/H/A-20/1419 |

<div style=\"page-break-after: always\"></div>

|                     | suspended or revoked. As the request results from the evaluation of data resulting from pharmacovigilance activities, the CHMP opinion should be adopted on the basis of a recommendation of the Pharmacovigilance Risk Assessment Committee. The notification for the procedure is appended to this recommendation.   |            |     |                                   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| IG/0654             | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                           | 29/02/2016 | n/a |                                   |
| IG/0653             | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                           | 29/02/2016 | n/a |                                   |
| PSUSA/10294 /201507 | Periodic Safety Update EU Single assessment - dapagliflozin / metformin                                                                                                                                                                                                                                                | 11/02/2016 | n/a | PRAC Recommendation - maintenance |
| IG/0643             | B.II.f.1.e - Stability of FP - Change to an approved stability protocol                                                                                                                                                                                                                                                | 12/01/2016 | n/a |                                   |
| WS/0824/G           | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No                                                                                                                                                                           | 10/12/2015 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

|                     | 1234/2008. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation   |            |     |                                   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| IG/0633             | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                                                                                                                                    | 09/12/2015 | n/a |                                   |
| PSUSA/10294 /201501 | Periodic Safety Update EU Single assessment - dapagliflozin / metformin                                                                                                                                                                                                                                                                                                                                                            | 10/09/2015 | n/a | PRAC Recommendation - maintenance |
| IG/0576             | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                        | 26/06/2015 | n/a |                                   |
| IG/0522             | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                                                                                                                                    | 12/03/2015 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

| IAIN/0009/G         | This was an application for a group of variations.                      | 17/02/2015   | 11/02/2016   | Annex II and PL   |                                   |
|---------------------|-------------------------------------------------------------------------|--------------|--------------|-------------------|-----------------------------------|
| PSUSA/10294 /201407 | Periodic Safety Update EU Single assessment - dapagliflozin / metformin | 12/02/2015   | n/a          |                   | PRAC Recommendation - maintenance |

<div style=\"page-break-after: always\"></div>

| WS/0601/G   | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing including the RMP - Other variation   | 22/01/2015   | n/a        |                        | authorisation,   |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|------------------|
| IG/0486     | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 28/11/2014   | n/a        |                        |                  |
| T/0005      | Transfer of Marketing Authorisation fom Bristol- Myers Squibb/AstraZeneca EEIG to AstraZeneca AB. Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 23/09/2014   | 03/10/2014 | SmPC, Labelling and PL |                  |
| WS/0536     | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 24/07/2014   | 03/10/2014 | SmPC                   |                  |

<div style=\"page-break-after: always\"></div>

|         | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                                                            |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0510 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                              | 24/07/2014 | 03/10/2014 | SmPC and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| WS/0537 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of section 5.1 of the SmPC of Xigduo (dapaglifozin and metformin) and Forxiga (dapaglifozin) in order to reflect the long-term findings from 208 weeks (4 years) of administration of dapagliflozin as add-on-to metformin compared with a sulphonylurea (SU; i.e, glipizide) as add-on to metformin. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 22/05/2014 | 03/10/2014 | SmPC        | The up to 4 years safety and efficacy data has been reported in the clinical study report of study D1690C00004. Based on it the MAH has updated section 5.1 of the SmPC of Xigduo (dapaglifozin and metformin) and Forxiga (dapaglifozin) in order to reflect the long-term findings from 208 weeks of administration of dapagliflozin as add- on-to metformin compared with a sulphonylurea (glipizide) as add-on to metformin. The study was designed to show non-inferiority for dapagliflozin versus glipizide at 52 weeks and the primary endpoint was met. At the end of the first extension period (LT1) some deterioration of HbA1c was observed, however, less prominent for dapagliflozin with a between treatment difference of 0.18 %. During the LT2 extension, HbA1c continued to rise but slower in the dapagliflozin treated group than in the glipizide treated group, resulting in a between treatment difference of - 0.30% at 208 weeks. Overall about 20% of patients completed the study without the need for rescue medication in both treatment groups |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                |            |            |             | (20% vs 18 %, dapagliflozin and glipizide respectively) thus managed to maintain an acceptable metabolic control for four years with either dapagliflozin or glipizide. Due to the progressive nature of T2DM it is well known that treatment has to be intensified over time and maintaining effect over four years is considered clinically relevant albeit in a limited proportion of the patients. The data also show that the effect of both treatments on body weight, which had stabilised for both treatments at 52 weeks, was maintained over the study duration resulting in a decrease in body weight (compared to baseline) of about -3.5 kg in the dapagliflozin treated group and a treatment difference of 4.38 kg at week 208. The safety data provided (up to 208 weeks treatment) confirm the safety profile known for dapagliflozin. The most common AEs are related to the increased excretion of urinary glucose, i.e. genital infections and UTI (urinary tract infections); there appears to be no increase in serious UTI over time compared to glipizide treatment. In conclusion, the data provided support the long-term use of dapagliflozin in the treatment of T2DM. The data supporting a maintained efficacy, both with regards to HbA1c and body weight, over the 208 week study period for a relevant proportion of patients is considered of relevance for the prescriber and the changes proposed to section 5.1 is therefore accepted. This application was submitted for a Type II variation, following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.   |
|---------|------------------------------------------------------------------------------------------------|------------|------------|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0002 | Update of sections 4.2, 4.8 and 5.1 of the SmPC order to reflect the up to 24 weeks safety and | 25/04/2014 | 03/10/2014 | SmPC and PL | The Marketing Authorisation Holder (MAH) submitted study D1693C00005 clinical study report (CSR) in order to                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

| efficacy results reported in study D1693C00005 Clinical Study Report (CSR), study that investigated dapagliflozin as add-on therapy to metformin and a sulphonylurea for the treatment of subjects with Type 2 Diabetes who have inadequate glycaemic control on a background combination of metformin and sulphonylurea. The Package Leaflet is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance   | data   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|